Место макролидов в антибактериальной терапии инфекций нижних дыхательных путей

1. Аnthonisen NR, Manfreda J, Warren CP et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106, 196–204.
2. The New Macrolides, Azalides, and Streptogramins.Clin Pharmacy 1992; 11: 137–52.
3. Blasi F, Damato S, Cosentini R et al. The Chlamydia Interаction with COPD (CIAC) Study Group. Chlamydia pneumoniae and chronic bronchitis: association with severity and bacterial clearance following treatment. Thorax 2002; 57: 672–6.
4. Peters DH, Friedel HA, McTavish D. Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drug 1992; 44: 750–99.
5. DeAbate CA, Mathew CP, Warmer JH et al. The safety and efficacy of short cours (5-day) moxifloxacin versus asithromycin in the treatment of patients with acute exacerbacion of chronic bronchitis. Respir Med 2000; 94, 1029–103.
6. Amsden GW, Baird, Ian M et al. Efficacy and Safety of Azithromycin vs Levofloxacin in the Outpatient Treatment of Acute Bacterial Exacerbations of Chronic Bronchitis. Chest 2003; 123: 772–7.
7. Siempos I, Dimopoulos G, Korbila I et al. Macrolides, quinolones and amoxicillin/clavulanate for chronic bronchitis: a meta-analysis. Eur Respir J 2007; 29: 1127–37.
8. Синопальников А.И. и др. Рос. мед. вестник. 2006; 12: 4–18.
9. Pechere J, Hughes D, Kardas P, Cornaglia G. Non compliance with antibiotic therapy for acute community infections: a global survey. Int J of Antimicrob Agents 2007; 29: 245–53.
10. Kardas P. Comparison of patient compliance with once-daily and twice-daily antibiotic regimens in respiratory tract infections: results of a randomized trial. J of Аntimicrob Сhemother 2007; 59 (3): 531–6.
11. Niederman MS. What are the benefits of antibiotics in acute exacerbations of COPD? 13th ERS Annual Congress, Vienna, 2003 personal communication.
12. «Три легких шага» в лечении инфекций дыхательных путей. Аптека. 2002; 41.
13. Внебольничная пневмония у взрослых. Практические рекомендации по диагностике, лечению и профилактике. Пособие для врачей. М., 2010.
14. Shefet D, Robenshtok E, Paul M, Leibovici L. Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized controlled trials. Arch Intern Med 2005; 165 (17): 1992–2000.
15. Martinez JA, Horcajada JP, Almela M еt al. Addition of macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower inhospitality mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003; 36: 389–95.
16. Синопальников А.И., Первов Ю.А., Богданов М.А., Раков А.Л. Пилотное исследование длительной профилактики азитромицином острых бактериальных инфекций дыхательных путей у военнослужащих. Клин.  микробиология и антимикроб. химиотерапия. 2000, 2: 31–6.
17. Gray GC, McPhate D, Leinonen M et al. Weekly oral azithromycin as prophylactic therapy causes of acute respiratory disease. Clin Infect Dis 1998, 26: 103–10.
18. SuPoRTI: Sumamed Post-marketing Study in RTI. 2009.
19. Козлов Р.С., Крешков О.И., Сивая О.В. и др. Антимикробная резистентность Streptococcus pneumoniae в России: результаты проспективного многоцентрового исследования (фаза А проект ПеГАС-1). Клин. микробиология и антимикроб. химиотерапия. 2002; 3: 20.
20. Paran Y, Mashav N, Henis O et al. Drug-induced torsades de pointes in patients aged 80 years or more. Anadolu Kardiyol Derg 2008; 8 (4): 260–5.
21. Russo V, Puzio G, Siniscalchi N. Azithromycin-induced QT prolongation in elderly patient. Acta Biomed 2006; 77 (1): 30–2.

Л.И.Дворецкий

Первый МГМУ им. И.М.Сеченова